Bristol-Myers hepatitis C drug gets approval in Japan

July 7 Mon Jul 7, 2014 7:41am EDT

July 7 (Reuters) - Bristol-Myers Squibb and Co said its combination drug for the treatment of hepatitis C was approved in Japan.

The treatment, which comprises Daklinza and Sunvepra drugs, is meant for patients who are intolerant or have failed to respond to standard medication. (Reporting By Penumudi Amrutha in Bangalore; Editing by Don Sebastian)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.